Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response
University of Colorado, Denver
100 participants
Nov 11, 2015
OBSERVATIONAL
Conditions
Summary
This study plans to evaluate the effects of chronic cannabis smoking on lung health by evaluating its effects on pulmonary health, lung physiology and alveolar macrophage function.
Eligibility
Inclusion Criteria6
- Daily or near daily cannabis use (inhaled via joint/cigarette or pipe) equivalent to AT LEAST 20 "joint years" (number of joints/cigarettes per day multiplied by number of years during which cannabis was smoked) by self-report and validated through urine drug screen.
- Never or limited exposure to inhaled tobacco products (equivalent to LESS THAN one "pack year" in a lifetime) by selfreport and validated through negative urine cotinine screen.
- Capacity to answer screening questions and provide informed consent at time of interview, along with contact information
- No cannabis use ever by self-report, and validated through urine drug screen.
- Never users of tobacco/cigarettes
- Capacity to answer screening questions and provide informed consent at time of interview, along with contact information.
Exclusion Criteria38
- LESS THAN near daily cannabis use (inhaled via joint/cigarette or pipe) equivalent to LESS THAN 20 "joint years" (number of joints/cigarettes per day multiplied by number of years during which cannabis was smoked) or a negative urine drug screen (for cannabis)
- Inhaled tobacco product exposure EXCEEDING one "pack year" or a positive urine cotinine screen
- Elevated AUDIT-C score: A 3 item questionnaire to identify subjects with alcohol use disorders.
- Prior medical history of liver disease: cirrhosis, total bilirubin > 2.0 mg/dL or albumin <3
- Prior medical history of myocardial infarction or congestive heart failure
- Prior medical history of end-stage renal disease or serum creatinine >3 mg/dL
- Prior history of or current use of illicit drug use defined as a positive toxicology screen for opiates or cocaine
- Prior history of diabetes mellitus
- Prior history of chronic obstructive pulmonary disease (COPD) or asthma that is not clinically controlled (have not required systemic corticosteroids in the past month)
- Prior history of HIV, not controlled or on medication
- Peripheral white blood cell count of less than 3000
- Acute worsening (<7 days) in respiratory symptoms (such as change in cough frequency or sputum production, fever, dyspnea, abnormal chest radiograph), or room air pulse oximetry of < 92% at rest or spirometry of < 50% predicted for FEV1 and FVC
- Use of systemic antibiotics for any reason in the past month (4 weeks)
- Failure of a subject or the subject's substance abuse counselor to provide assent
- Nutritional risk index of less than 95
- Age < 21 or > 55 (using an age of 55 limits the likelihood of comorbid conditions that may increase the risk of adverse events with bronchoscopy)
- Pregnancy
- Decisionally challenged
- Prisoners.
- History of inhaled cannabis exposure EXCEEDING one "joint year" or positive urine toxicology screen (for cannabis)
- History of inhaled tobacco product exposure EXCEEDING one "pack year" or a positive urine cotinine screen
- Elevated AUDIT-C score: A 3 item questionnaire to identify subjects with alcohol use disorders.
- Prior medical history of liver disease: cirrhosis, total bilirubin > 2.0 mg/dL or albumin <3
- Prior medical history of myocardial infarction or congestive heart failure
- Prior medical history of end-stage renal disease or serum creatinine >3 mg/dL
- Prior history of or current use of illicit drug use defined as a positive toxicology screen for opiates or cocaine
- Prior history of diabetes mellitus
- Prior history of chronic obstructive pulmonary disease (COPD) or asthma that is not clinically controlled (have not required systemic corticosteroids in the past month)
- Prior history of HIV, not controlled or on medication
- Peripheral white blood cell count of less than 3000
- Acute worsening (<7 days) in respiratory symptoms (such as change in cough frequency or sputum production, fever, dyspnea, abnormal chest radiograph), or room air pulse oximetry of < 92% at rest or spirometry of < 50% predicted for FEV1 and FVC
- Use of systemic antibiotics in the past month (4 weeks)
- Failure of a subject or the subject's substance abuse counselor to provide assent
- Nutritional risk index of less than 95
- Age < 21 or > 55
- Pregnancy
- Decisionally challenged
- Prisoners.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
To collect blood cells and serum for analyses.
To administer the appropriate medications for the bronchoscopy procedure.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02480283